CHMP Backs Lynavoy for PBC Itch
CHMP Lynavoy linerixibat PBC pruritus recommendation moves GSK's ileal bile-acid transporter inhibitor toward EU authorisation for a symptom that dominates quality of life in primary biliary cholangitis. EMA listed the positive opinion in its 20–23 July 2026 CHMP highlights.
Contents9 sections
Key Takeaways
- CHMP recommended Lynavoy for cholestatic pruritus in adult PBC.
- UK MHRA already approved Lynavoy on 1 May 2026 via national procedure.
- Phase 3 Glisten supported itch and sleep-disruption improvements versus placebo.
- EC centralised decision is the next EU step after CHMP.
Lynavoy CHMP opinion at a glance
| Field | Detail |
|---|---|
| Product | Lynavoy (linerixibat) |
| Company | GSK |
| Indication sought | Cholestatic pruritus in adults with primary biliary cholangitis |
| EU status | CHMP positive opinion (July 2026) |
| UK status | MHRA approved 1 May 2026 |
| Pivotal trial | Glisten Phase 3 (n=238; 24 weeks) |
| UK dose cited | One film-coated tablet twice daily |
What did EMA announce?
EMA said Lynavoy received a positive CHMP opinion for adults with cholestatic pruritus complicating PBC. The agency explained that bile-duct destruction leads to bile-acid accumulation and intense itching — a symptom often poorly controlled by existing ursodeoxycholic acid–centred disease therapy alone.
Source: EMA CHMP meeting highlights for 20–23 July 2026.
What did the UK already approve?
MHRA approved Lynavoy on 1 May 2026 for itch in adults with PBC. The agency summarised Glisten: 238 patients randomised to linerixibat 40 mg twice daily or placebo for 24 weeks, with statistically significant Monthly Itch Score improvement and better sleep disruption related to itch. Recommended UK dosing is one tablet twice daily.
Source: MHRA's 1 May 2026 Lynavoy approval notice. Trial records can be browsed on ClinicalTrials.gov.
Why does PBC itch matter clinically?
- Pruritus can be severe, sleep-disrupting, and refractory
- Symptom control is often separate from biochemical disease-modifying goals
- An oral IBAT inhibitor offers a mechanism aimed at bile-acid enterohepatic recirculation
CHMP's opinion does not by itself set SmPC wording for the EU; clinicians should wait for the Commission decision and the published EU Product Information before treating it as authorised therapy across member states. For rare-liver clinics, the practical question after authorisation will be how Lynavoy fits alongside ursodeoxycholic acid, obeticholic acid or fibrates used for disease control, and whether payers treat itch relief as a reimbursable endpoint independent of alkaline-phosphatase response.
UK experience after the May MHRA approval may offer early real-world signals on diarrhoea tolerability, adherence to twice-daily dosing, and sleep-score changes, but those observations should not be imported wholesale into EU labelling assumptions until the centralised SmPC is published.
What remains uncertain?
EU label details, hepatic safety monitoring, and diarrhoea rates typical of IBAT inhibitors will matter for uptake. National reimbursement for a symptom-focused rare-liver indication can lag EC authorisation. Cross-reading UK SmPC language into EU practice before centralised approval would be premature.
Related NovaPharma coverage
- CHMP July 2026: 12 New Medicines Recommended
- JASCAYD Wins EU Approval for IPF & PPF
- EU/UK Regulator Round-up: 20 July 2026
Frequently Asked Questions
What did CHMP recommend for Lynavoy?
EMA said CHMP gave a positive opinion for Lynavoy (linerixibat) for adults with cholestatic pruritus associated with primary biliary cholangitis, an autoimmune disease that gradually destroys bile ducts and can cause intense itching from bile-acid buildup.
Is Lynavoy already approved in the UK?
Yes. The UK MHRA approved linerixibat (Lynavoy) on 1 May 2026 for itch in adults with primary biliary cholangitis, citing the Phase 3 Glisten trial in which 238 patients received linerixibat 40 mg twice daily or placebo for 24 weeks and showed significant Monthly Itch Score improvement.
What happens after the CHMP opinion?
The opinion goes to the European Commission for a centralised marketing-authorisation decision. Member-state pricing and reimbursement decisions follow separately after any EC authorisation.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Lynavoy.
Unlock full calendar →GSK pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…